Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Background Programming long arrhythmia detection times can reduce the incidence of
implantable cardioverter-defibrillator (ICD) shock therapy. However, potential concerns exist …

Смертность от сердечнососудистых заболе ваний в России является одной из
наиболее высоких в мире и составляет 1462 на 100 000 жителей в год [1]. Основные …

Despite the increasingly high rate of implantation of pacemakers (PMs) and implantable
cardioverter defibrillators (ICDs) in elderly patients, data supporting their clinical and cost …

Background Routine addition of an atrial lead during an implantable cardioverter‐
defibrillator (ICD) implantation for primary prevention of sudden cardiac death, in patients …

Представленные рекомендации разработаны на основе современных достижений
отечественных и зарубежных специалистов, рассматриваются вопросы …

Implantable cardioverter-defibrillators (ICDs) reduce sudden cardiac death risk and improve
survival in patients with a history of life-threatening arrhythmia or cardiac arrest (secondary …

Abstract Objectives: The OPTION (Optimal Anti-Tachycardia Therapy in Implantable
Cardioverter-Defibrillator Patients Without Pacing Indications) trial sought to compare long …

Aims To evaluate the incidences of and risk factors predisposing to appropriate and
inappropriate shocks and mortality in a 'real-world'population of patients with ischaemic …